Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Claudia Marchetti, Carmela Pisano, Gaetano Facchini, Giovanni Salvatore Bruni, Francesca Paola Magazzino, Simona Losito & Sandro Pignata. (2010) First-line treatment of advanced ovarian cancer: current research and perspectives. Expert Review of Anticancer Therapy 10:1, pages 47-60.
Read now
Read now
Chris Ireland, William Aalbersberg, Raymond Andersen, Semiramis Ayral-Kaloustian, Roberto Berlinck, Valerie Bernan, Guy Carter, Alice Churchill, Jon Clardy, Gisela Concepcion, E. De Silva, Carolyn Discafani, Tito Fojo, Philip Frost, Donna Gibson, Lee Greenberger, Michael Greenstein, Mary Kay Harper, Robert Mallon, Frank Loganzo, Maria Nunes, Marianne Poruchynsky & Arie Zask. (2003) Anticancer Agents from Unique Natural Products Sources. Pharmaceutical Biology 41:sup1, pages 15-38.
Read now
Read now
John C Kath. (2000) Patent focus: inhibitors of tumour cell growth. Expert Opinion on Therapeutic Patents 10:6, pages 803-818.
Read now
Read now
Peggy A Scherle & James M Trzaskos. (1999) Kinase targets in inflammation. Emerging Therapeutic Targets 3:1, pages 1-25.
Read now
Read now
Joseph L Evans & Bahija Jallal. (1999) Protein tyrosine phosphatases: their role in insulin action and potential as drug targets. Expert Opinion on Investigational Drugs 8:2, pages 139-160.
Read now
Read now
Articles from other publishers (47)
Ayman Abo Elmaaty, Khaled M. Darwish, Amani Chrouda, Amira A. Boseila, Mohamed A. Tantawy, Sameh S. Elhady, Afzal B. Shaik, Muhamad Mustafa & Ahmed A. Al-karmalawy. (2021) In Silico and In Vitro Studies for Benzimidazole Anthelmintics Repurposing as VEGFR-2 Antagonists: Novel Mebendazole-Loaded Mixed Micelles with Enhanced Dissolution and Anticancer Activity. ACS Omega 7:1, pages 875-899.
Crossref
Crossref
Hazem A. Mahdy, Mohammed K. Ibrahim, Ahmed M. Metwaly, Amany Belal, Ahmed B.M. Mehany, Kamal M.A. El-Gamal, Abdou El-Sharkawy, Mostafa A. Elhendawy, Mohamed M. Radwan, Mahmoud A. Elsohly & Ibrahim H. Eissa. (2020) Design, synthesis, molecular modeling, in vivo studies and anticancer evaluation of quinazolin-4(3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers. Bioorganic Chemistry 94, pages 103422.
Crossref
Crossref
Weijie Gu, Yuxuan Dai, Hao Qiang, Wei Shi, Chen Liao, Fangnuo Zhao, Wenlong Huang & Hai Qian. (2017) Discovery of novel 2-substituted-4-(2-fluorophenoxy) pyridine derivatives possessing pyrazolone and triazole moieties as dual c-Met/VEGFR-2 receptor tyrosine kinase inhibitors. Bioorganic Chemistry 72, pages 116-122.
Crossref
Crossref
Xuebao Wang, Di Chen, Shufang Yu, Zaikui Zhang, Yu Wang, Xiaolu Qi, Weitao Fu, Zixin Xie & Faqing Ye. (2016) Synthesis and Evaluation of Biological and Antitumor Activities of Tetrahydrobenzothieno[2,3-d]Pyrimidine Derivatives as Novel Inhibitors of FGFR1. Chemical Biology & Drug Design 87:4, pages 499-507.
Crossref
Crossref
Ying Huang, Zakaria Rachid, Lisa Peyrard, Zhor Senhaji Mouhri, Christopher Williams & Bertrand J. Jean-Claude. (2015) Positional Isomerization of A Non-Cleavable Combi-Molecule Dramatically Altered Tumor Cell Response Profile. Chemical Biology & Drug Design 85:2, pages 153-162.
Crossref
Crossref
Naoki Miyamoto, Nozomu Sakai, Takaharu Hirayama, Kazuhiro Miwa, Yuya Oguro, Hideyuki Oki, Kengo Okada, Terufumi Takagi, Hidehisa Iwata, Yoshiko Awazu, Seiji Yamasaki, Toshiyuki Takeuchi, Hiroshi Miki, Akira Hori & Shinichi Imamura. (2013) Discovery of N -[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2- b ]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1 H -pyrazole-5-carboxamide (TAK-593), a highly potent VEGFR2 kinase inhibitor. Bioorganic & Medicinal Chemistry 21:8, pages 2333-2345.
Crossref
Crossref
Naoki Miyamoto, Yuya Oguro, Terufumi Takagi, Hidehisa Iwata, Hiroshi Miki, Akira Hori & Shinichi Imamura. (2012) Design, synthesis, and evaluation of imidazo[1,2-b]pyridazine derivatives having a benzamide unit as novel VEGFR2 kinase inhibitors. Bioorganic & Medicinal Chemistry 20:24, pages 7051-7058.
Crossref
Crossref
John J. Haddad. (2012) The immunopharmacologic potential of Semaxanib and new generation directed therapeutic drugs: Receptor tyrosine kinase regulation with anti-tumorigenensis/angiogenesis properties. Saudi Pharmaceutical Journal 20:2, pages 103-123.
Crossref
Crossref
She-Juan An, Zhi-Hong Chen, Qiu-Xiong Lin, Jian Su, Hua-Jun Chen, Jia-Ying Lin & Yi-Long Wu. (2009) The -271 G>A polymorphism of kinase insert domain-containing receptor gene regulates its transcription level in patients with non-small cell lung cancer. BMC Cancer 9:1.
Crossref
Crossref
Paola Barraja, Virginia Span?Patrizia Diana, Anna Carbone & Girolamo Cirrincione. (2009) Synthesis of the new ring system 6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline. Tetrahedron Letters 50:38, pages 5389-5391.
Crossref
Crossref
Russell J. Schilder, Harsh B. Pathak, Anna E. Lokshin, Robert W. Holloway, Ronald D. Alvarez, Carol Aghajanian, Hua Min, Karthik Devarajan, Eric Ross, Charles W. Drescher & Andrew K. Godwin. (2009) Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecologic Oncology 113:1, pages 21-27.
Crossref
Crossref
Jason Konner, Russell J. Schilder, Felicia A. DeRosa, Scott R. Gerst, William P. Tew, Paul J. Sabbatini, Martee L. Hensley, David R. Spriggs & Carol A. Aghajanian. (2008) A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecologic Oncology 110:2, pages 140-145.
Crossref
Crossref
Andrew J. Li, Daniel R. Scoles, Klara U.M. Armstrong & Beth Y. Karlan. (2008) Androgen receptor cytosine-adenine-guanine repeat polymorphisms modulate EGFR signaling in epithelial ovarian carcinomas. Gynecologic Oncology 109:2, pages 220-225.
Crossref
Crossref
Zhiqin Ji, Asma A. Ahmed, Daniel H. Albert, Jennifer J. Bouska, Peter F. Bousquet, George, A. Cunha, Gilbert Diaz, Keith B. Glaser, Jun Guo, Christopher M. Harris, Junling Li, Patrick A. Marcotte, Maria D. Moskey, Tetsuro Oie, Lori Pease, Nirupama B. Soni, Kent D. Stewart, Steven K. Davidsen & Michael R. Michaelides. (2008)
3-Amino-benzo[
d
]isoxazoles as Novel Multitargeted Inhibitors of Receptor Tyrosine Kinases
. Journal of Medicinal Chemistry 51:5, pages 1231-1241.
Crossref
Crossref
Yun Oh, Michael Lahn, Asavari Wagle & Roy Herbst. 2007. Targeted Therapies in Oncology. Targeted Therapies in Oncology
103
121
.
Naparat Kammasud, Chantana Boonyarat, Satoshi Tsunoda, Hiroaki Sakurai, Ikuo Saiki, David S. Grierson & Opa Vajragupta. (2007) Novel inhibitor for fibroblast growth factor receptor tyrosine kinase. Bioorganic & Medicinal Chemistry Letters 17:17, pages 4812-4818.
Crossref
Crossref
She-Juan An, Qiang Nie, Zhi-Hong Chen, Qiu-Xiong Lin, Zhen Wang, Zhi Xie, Shi-Liang Chen, Ying Huang, Ai-Ye Zhang, Jin-Feng Yan, Hong-Sui Wu, Jia-Ying Lin, Rong Li, Xu-Chao Zhang, Ai-Lin Guo, Tony S. Mok & Yi-Long Wu. (2007) KDR expression is associated with the stage and cigarette smoking of the patients with lung cancer. Journal of Cancer Research and Clinical Oncology 133:9, pages 635-642.
Crossref
Crossref
Robert Campbell. 2006. Nanotechnology for Cancer Therapy. Nanotechnology for Cancer Therapy
613
627
.
Zhiqin Ji, Asma A. Ahmed, Daniel H. Albert, Jennifer J. Bouska, Peter F. Bousquet, George A. Cunha, Keith B. Glaser, Jun Guo, Junling Li, Patrick A. Marcotte, Maria D. Moskey, Lori J. Pease, Kent D. Stewart, Melinda Yates, Steven K. Davidsen & Michael R. Michaelides. (2006) Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases. Bioorganic & Medicinal Chemistry Letters 16:16, pages 4326-4330.
Crossref
Crossref
Elitza Naumova, Paolo Ubezio, Angela Garofalo, Patrizia Borsotti, Linda Cassis, Elena Riccardi, Eugenio Scanziani, Suzanne A. Eccles, Maria R. Bani & Raffaella Giavazzi. (2006) The Vascular Targeting Property of Paclitaxel Is Enhanced by SU6668, a Receptor Tyrosine Kinase Inhibitor, Causing Apoptosis of Endothelial Cells and Inhibition of Angiogenesis. Clinical Cancer Research 12:6, pages 1839-1849.
Crossref
Crossref
Russell J. Schilder, Michael W. Sill, Xiaowei Chen, Kathleen M. Darcy, Steven L. Decesare, George Lewandowski, Roger B. Lee, Cletus A. Arciero, Hong Wu & Andrew K. Godwin. (2005) Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study. Clinical Cancer Research 11:15, pages 5539-5548.
Crossref
Crossref
David Moffat, Christopher J. Nichols, Dean A. Riley & Nigel S. Simpkins. (2005) The synthesis of bioactive indolocarbazoles related to K-252a. Organic & Biomolecular Chemistry 3:16, pages 2953.
Crossref
Crossref
D. Fabbro, G. Fendrich, V. Guez, T. Meyer, P. Furet, J. Mestan, J. D. Griffin, P. W. Manley & S. W. Cowan-Jacob. 2005. Inhibitors of Protein Kinases and Protein Phosphates. Inhibitors of Protein Kinases and Protein Phosphates
361
389
.
T. K. Sawyer, R. S. Bohacek, W. C. Shakespeare, C. A. MetcalfIIIIII, Y. Wang, R. Sundaramoorthi, T. Keenan, S. Narula & D. C. Dalgarno. 2005. Proteomics and Protein-Protein Interactions. Proteomics and Protein-Protein Interactions
219
253
.
Nancy A. Dawson, Chuanfo Guo, Richard Zak, Brenda Dorsey, Jeanne Smoot, Jade Wong & Arif Hussain. (2004) A Phase II Trial of Gefitinib (Iressa, ZD1839) in Stage IV and Recurrent Renal Cell Carcinoma. Clinical Cancer Research 10:23, pages 7812-7819.
Crossref
Crossref
Eric K. Rowinsky, Garry H. Schwartz, Jared A. Gollob, John A. Thompson, Nicholas J. Vogelzang, Robert Figlin, Ronald Bukowski, Naomi Haas, Pamela Lockbaum, Yu-Ping Li, Rosalin Arends, Kenneth A. Foon, Gisela Schwab & Janice Dutcher. (2004) Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer. Journal of Clinical Oncology 22:15, pages 3003-3015.
Crossref
Crossref
Samit K. Bhattacharya, Eric D. Cox, John C. Kath, Alan M. Mathiowetz, Joel Morris, James D. Moyer, Leslie R. Pustilnik, Kris Rafidi, Daniel T. Richter, Chunyan Su & Matthew D. Wessel. (2003) Achieving selectivity between highly homologous tyrosine kinases: a novel selective erbB2 inhibitor. Biochemical and Biophysical Research Communications 307:2, pages 267-273.
Crossref
Crossref
Glenda Bilder, Dilip Amin, Lisa Morgan, Matthew McVey, Saul Needle, Helen Galczenski, Robert Leadley, Wei He, Michael Myers, Alfred Spada, Yongyi Luo, Chandra Natajaran & Mark Perrone. (2003) Stent-induced Restenosis in the Swine Coronary Artery Is Inhibited by a Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor, TKI963. Journal of Cardiovascular Pharmacology 41:6, pages 817-829.
Crossref
Crossref
Carlos L Arteaga, Fadlo Khuri, Geoffrey Krystal & Said Sebti. (2002) Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. Seminars in Oncology 29:1, pages 15-26.
Crossref
Crossref
Wynne Aherne, Michelle Garrett, Ted McDonald & Paul Workman. 2002. Anticancer Drug Development. Anticancer Drug Development
249
267
.
Lucia Morbidelli & Marina Ziche. 2002. The New Angiotherapy. The New Angiotherapy
517
526
.
Laura K. Shawver, Kenneth E. Lipson, T. Annie T. Fong, Gerald McMahon & Laurie M. Strawn. 2002. The New Angiotherapy. The New Angiotherapy
409
452
.
Peter Traxler, Guido Bold, Elisabeth Buchdunger, Giorgio Caravatti, Pascal Furet, Paul Manley, Terence O'Reilly, Jeanette Wood & Juerg Zimmermann. (2001) Tyrosine kinase inhibitors: From rational design to clinical trials. Medicinal Research Reviews 21:6, pages 499-512.
Crossref
Crossref
Alex Matter. (2001) Tumor angiogenesis as a therapeutic target. Drug Discovery Today 6:19, pages 1005-1024.
Crossref
Crossref
Christos Papageorgiou, Gian Camenisch & Xaver Borer. (2001) Cell permeability as a parameter for lead generation in the protein Tyrosine kinase inhibition field. Bioorganic & Medicinal Chemistry Letters 11:12, pages 1549-1552.
Crossref
Crossref
Paul A. Renhowe. 2001.
109
118
.
Kenneth Lipson, Li Sun, Congxin Liang & Gerald McMahon. 2000. Cytokine Inhibitors. Cytokine Inhibitors.
Paul A Clarke, Isabelle Hostein, Udai Banerji, Francesca Di Stefano, Alison Maloney, Mike Walton, Ian Judson & Paul Workman. (2000) Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 19:36, pages 4125-4133.
Crossref
Crossref
G. Tortora & F. Ciardiello. (2000) Targeting of epidermal growth factor receptor and protein kinase A: Molecular basis and therapeutic applications. Annals of Oncology 11:7, pages 777-783.
Crossref
Crossref
Gerald McMahon. (2000) VEGF Receptor Signaling in Tumor Angiogenesis. The Oncologist 5:S1, pages 3-10.
Crossref
Crossref
Julie M. Cherrington, Laurie M. Strawn & Laura K. Shawver. 2000.
1
38
.
Dean B. Evans, Peter Traxler & Carlos García-Echeverría. 2000. New Approaches to Drug Development. New Approaches to Drug Development
123
139
.
Carlos Garc�a-Echeverr�a, Peter Traxler & Dean B. Evans. (2000) ATP site-directed competitive and irreversible inhibitors of protein kinases. Medicinal Research Reviews 20:1, pages 28-57.
Crossref
Crossref
M.D. Garrett & P. Workman. (1999) Discovering novel chemotherapeutic drugs for the third millennium. European Journal of Cancer 35:14, pages 2010-2030.
Crossref
Crossref
M. Ziche, C. Sorriso, A. Parenti, L. Brogelli, C. Tricarico, D. Villari & M. Pazzagli. (2018) Biological Parameters for the Choice of Antiangiogenic Therapy and Efficacy Monitoring. The International Journal of Biological Markers 14:4, pages 214-217.
Crossref
Crossref
Péter Nagy, Attila Jenei, Achim K. Kirsch, János Szöllősi, Sándor Damjanovich & Thomas M. Jovin. (1999) Activation-dependent clustering of the erbB2 receptor tyrosine kinase detected by scanning near-field optical microscopy. Journal of Cell Science 112:11, pages 1733-1741.
Crossref
Crossref
James M Hamby & H.D.Hollis Showalter. (1999) Small Molecule Inhibitors of Tumor-Promoted Angiogenesis, Including Protein Tyrosine Kinase Inhibitors. Pharmacology & Therapeutics 82:2-3, pages 169-193.
Crossref
Crossref